drmema2 t1_jcjzhc4 wrote on March 17, 2023 at 11:52 AM Reply to A new targeted drug has not only sparked remissions in patients with a common form of leukemia but also induced the cancer cells to reveal one of their schemes for resisting the drug, according to a new study by chrisdh79 my partner was treated for AML NTM mutation in a gilteritinib trial in 2017 and is still in remission thank God for this work. Ten years ago or more AML had a poor survival rate. Permalink 1
drmema2 t1_jcjzhc4 wrote
Reply to A new targeted drug has not only sparked remissions in patients with a common form of leukemia but also induced the cancer cells to reveal one of their schemes for resisting the drug, according to a new study by chrisdh79
my partner was treated for AML NTM mutation in a gilteritinib trial in 2017 and is still in remission thank God for this work. Ten years ago or more AML had a poor survival rate.